Loading clinical trials...
Loading clinical trials...
Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant
Extended Venous Thromboemboism Prophylaxis After Bariatric Surgeries: A Comparison Of Low Molecular Weight Heparin With Direct Oral Anticoagulant
This study aims to compare the effectiveness of rivaroxaban versus low molecular weight heparin in reducing the incidence of PMVT after bariatric surgery.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Cairo University
Cairo, Egypt
Start Date
March 25, 2024
Primary Completion Date
October 25, 2025
Completion Date
November 1, 2025
Last Updated
August 26, 2025
100
ESTIMATED participants
Direct Oral Anticoagulant.
DRUG
Low Molecular Weight Heparine
DRUG
Lead Sponsor
Cairo University
NCT05588284
NCT03050671
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05171075